Peptide Ligand Adsorbents for AAT Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying alpha-1 antitrypsin (AAT) face challenges such as high costs, liability to proteases, and inefficiencies in chromatographic processes, particularly in recombinant production and plasma fractionation, which limit the scalability and affordability of AAT manufacturing.
Innovation Solution
Development of novel peptide ligands with specific amino acid compositions and structures that bind AAT, conjugated to Toyopearl resins, enabling efficient purification from CHO cell culture fluids with high binding capacity and selectivity, reducing costs and maintaining resin performance across multiple uses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If camelid antibody fragment is used as affinity ligand for AAT capture, then binding capacity and selectivity are improved, but cost and lability to proteases increase
Solution Approach 1:
The patent uses peptide ligands that replicate the binding function of the camelid antibody fragment (affinity ligand) but with simpler, more stable sequences. These peptide copies maintain high binding capacity and selectivity for AAT while being more cost-effective and protease-resistant, directly resolving the contradiction between performance and manufacturing ease.
Solution Approach 2:
The peptide ligands are designed to be more economical alternatives to expensive protein-based affinity ligands. While individual peptide molecules may have shorter half-lives, their resistance to proteolysis in the harsh purification environment and lower replacement cost make them economically superior for industrial AAT purification processes.
2Reliability
If camelid antibody fragment is used as affinity ligand for AAT capture, then binding capacity and selectivity are improved, but lability towards proteases increases
Solution Approach 1:
The patent creates peptide copies that mimic the binding interface of the camelid antibody fragment but with enhanced protease resistance. These simplified peptide sequences maintain the essential binding interactions with AAT while being structurally more stable in the presence of proteases, resolving the contradiction between binding performance and stability.
3Quantity of substance
If plasma fractionation is used for AAT production, then availability is improved, but complexity and protein loss increase
Solution Approach 1:
The patent extracts and utilizes AAT directly from recombinant cell culture supernatants using peptide-based affinity chromatography, bypassing the complex multi-step plasma fractionation process. This extraction approach maintains high AAT availability while dramatically simplifying the manufacturing process by eliminating unnecessary intermediate steps.
4Productivity
If recombinant production is used for AAT, then scalability is improved, but downstream purification complexity increases
Solution Approach 1:
The patent employs simplified peptide ligand copies that enable efficient AAT capture from recombinant cell culture fluids. These peptide-based affinity materials provide high binding capacity and selectivity, allowing scalable recombinant production while reducing downstream purification complexity compared to traditional methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide ligand-based adsorbents achieve comparable yield and purity to commercial AAT Select resin while offering improved binding capacity and affordability, maintaining performance through repeated cycles and alkaline sanitization, demonstrating potential for scalable and cost-effective AAT manufacturing.
Implementation Method 1
novel peptide ligands capable of binding recombinantly produced α-1 antitrypsin to facilitate its isolation and/or purification from processing fluid streams
Data Source
AI summary
The present disclosure provides compositions and methods related to the purification and/or isolation of α-1 antitrypsin (AAT). In particular, the present disclosure provides novel peptide ligands capable of binding recombinantly produced α-1 antitrypsin to facilitate its isolation and/or purification from processing fluid streams for subsequent therapeutic use.